¥1,609.00
0.69%
Tokyo, Sep 18, 03:15 pm JST. Closed.
ISIN
JP3495000006
Symbol
4506
Index

Sumitomo Dainippon Pharma Target price 2026 - Analyst rating & recommendation

Sumitomo Dainippon Pharma Classifications & Recommendation

Buy
64%
Hold
36%

Sumitomo Dainippon Pharma Price Target

Target Price ¥1,887.00
Price ¥1,609.50
Potential
Number of Estimates 8
8 Analysts have issued a price target Sumitomo Dainippon Pharma 2027 . The average Sumitomo Dainippon Pharma target price is ¥1,887.00. This is higher than the current stock price. The highest price target is
¥2,835.00 76.14%
register free of charge
, the lowest is
¥1,515.00 5.87%
register free of charge
.
A rating was issued by 11 analysts: 7 Analysts recommend Sumitomo Dainippon Pharma to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2027 of . Most analysts recommend the Sumitomo Dainippon Pharma stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion ¥ 453.29 567.00
13.66% 25.08%
EBITDA Margin 16.57% 22.59%
71.15% 36.36%
Net Margin 23.58% 16.68%
297.84% 29.25%

8 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2027 . The average Sumitomo Dainippon Pharma sales estimate is

¥567b
unlock
. This is
19.42% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥617b 30.04%
unlock
, the lowest is
¥530b 11.73%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 ¥453b 13.66%
2027
¥567b 25.08%
unlock
2028
¥618b 9.05%
unlock
2029
¥623b 0.71%
unlock

8 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2027. The average Sumitomo Dainippon Pharma EBITDA estimate is

¥128b
unlock
. This is
4.78% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥148b 21.11%
unlock
, the lowest is
¥110b 10.12%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 ¥75.1b 94.52%
2027
¥128b 70.58%
unlock
2028
¥142b 10.53%
unlock
2029
¥112b 20.66%
unlock

EBITDA Margin

2026 16.57% 71.15%
2027
22.59% 36.36%
unlock
2028
22.90% 1.37%
unlock
2029
18.04% 21.22%
unlock

8 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2027. The average Sumitomo Dainippon Pharma net profit estimate is

¥94.6b
unlock
. This is
16.06% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥127b 12.33%
unlock
, the lowest is
¥75.6b 32.85%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 ¥107b 352.17%
2027
¥94.6b 11.52%
unlock
2028
¥93.2b 1.40%
unlock
2029
¥69.5b 25.41%
unlock

Net Margin

2026 23.58% 297.84%
2027
16.68% 29.25%
unlock
2028
15.08% 9.59%
unlock
2029
11.17% 25.93%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share ¥ 268.99 210.79
352.16% 21.64%
P/E 7.64
EV/Sales 1.40

8 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma EPS is

¥210.79
unlock
. This is
18.49% lower
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
¥282.10 9.09%
unlock
, the lowest is
¥168.64 34.79%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 ¥268.99 352.16%
2027
¥210.79 21.64%
unlock
2028
¥207.85 1.39%
unlock
2029
¥155.03 25.41%
unlock

P/E ratio

Current 6.22 82.44%
2027
7.64 22.75%
unlock
2028
7.74 1.31%
unlock
2029
10.38 34.11%
unlock

Based on analysts' sales estimates for 2027, the Sumitomo Dainippon Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.67 26.43%
2027
1.40 16.20%
unlock
2028
1.28 8.30%
unlock
2029
1.27 0.70%
unlock

P/S ratio

Current 1.51 6.42%
2027
1.26 16.26%
unlock
2028
1.16 8.30%
unlock
2029
1.15 0.71%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today